ART26.12 is the lead compound in Artelo's proprietary Fatty Acid Binding Protein (FABP) platform and is believed to be the first-ever selective FABP5 inhibitor to enter clinical trials.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
PURPOSE: To determine the expression of hepatic L-FABP and intestinal I-FABP in an experimental model of necrotizing enterocolitis (NEC) in neonatal rats. METHODS: Newborn Sprague-Dawley rats were ...
The compound was discovered and initially developed by Stony Brook University’s Iwao Ojima, PhD, and Martin Kaczocha, PhD.
Progression to the next cohort marks a major milestone in the development of Fatty Acid Binding Protein (FABP) inhibitors as a novel treatment approach for a large number of potential indications.
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
Data are accumulating that emphasize the important role of the intestinal barrier and intestinal permeability for health and disease. However, these terms are poorly defined, their assessment is a ...
After hours: January 31 at 4:02:55 PM EST Loading Chart for CARE ...
Exchange Bankshares, Inc. operates as the holding company for Exchange Bank that provides personal and business banking products and services in Georgia. It offers checking and savings accounts ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈